Dupixent 300 MG/2 ML pen 2ML
Ended Awarded Last action
- Contract number
- SPE2DR26F8N6L
- Awardee
-
Amerisourcebergen Drug Corp UEI KABZK8W6PQT3 Part of Cencora, Inc.
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $12,571
Award facts
- Contract value 100% obligated
- $12,570.65 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Conshohocken, PA 19428, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a delivery order valued at $12,570.65 to AmerisourceBergen Drug Corp for Dupixent 300 mg/2 ml pen injectors, with an ultimate completion date of January 22, 2026. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and will be performed at the contractor's location in Conshohocken, Pennsylvania. The award represents a task order issued under AmerisourceBergen's parent company Cencora, Inc.'s larger Indefinite Delivery Contract with DLA Troop Support Medical, valued at up to $999,999,999.00 through December 31, 2031, which serves as the primary vehicle for delivering pharmaceutical products and medical supplies to support military healthcare programs globally.
AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, fulfills a critical role in the federal medical procurement supply chain. The company's extensive contract portfolio with DLA demonstrates its capability to supply a comprehensive range of pharmaceutical products across multiple therapeutic domains to military treatment facilities, veterans' healthcare programs, and other federal medical institutions. Dupixent is a specialty biologic medication used primarily for atopic dermatitis and eosinophilic conditions, representing the type of specialized pharmaceutical commodity that supports the Department of Defense's healthcare operations worldwide.
Quick answers
Who was awarded contract SPE2DR26F8N6L?
SPE2DR26F8N6L was awarded to Amerisourcebergen Drug Corp by Defense Logistics Agency (Department of Defense) on January 21, 2026.
How much is contract SPE2DR26F8N6L worth?
The government has obligated $12,571 on SPE2DR26F8N6L.
Is contract SPE2DR26F8N6L an order under another contract?
Yes. SPE2DR26F8N6L is a delivery order under SPE2DR25D3022, an indefinite delivery contract.
Was contract SPE2DR26F8N6L competed?
The extent of competition for SPE2DR26F8N6L was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award